OCI-Ly18Homo sapiens (Human)Cancer cell line

Also known as: LY18, Ly18, OCI-Ly 18, OCILY18, OCI-LY-18, OCI-LY18, OCI-LZ18, SU-DHL-18

🤖 AI SummaryBased on 4 publications

Quick Overview

Human non-Hodgkin's lymphoma cell line with p53 mutations and c-myc rearrangements.

Detailed Summary

OCI-Ly18 is a human non-Hodgkin's lymphoma cell line derived from a patient with intermediate to high-grade lymphoma. It is characterized by the presence of p53 mutations and c-myc rearrangements, which are associated with aggressive disease progression. The cell line was part of a study examining genetic alterations in lymphoma cell lines, including p53, c-myc, and bcl-2. Research on OCI-Ly18 has contributed to understanding the molecular mechanisms underlying lymphoma development and progression, particularly in relation to oncogene activation and tumor suppressor gene mutations. The cell line is used in studies investigating the role of these genetic changes in lymphoma biology and therapeutic responses.

Research Applications

Oncogene activation studiesTumor suppressor gene mutationsGenetic alterations in lymphomaMolecular mechanisms of lymphoma progression

Key Characteristics

p53 mutationsc-myc rearrangementsB-cell lineage

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1880
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	56
Age Category	Adult
Sex	Male

Disease Information

Disease	Diffuse large B-cell lymphoma
Lineage	Lymphoid
Subtype	Diffuse Large B-Cell Lymphoma, NOS
OncoTree Code	DLBCLNOS

DepMap Information

Source Type	DSMZ
Source ID	ACH-001616_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	CDKN2A	p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT)	Unspecified	-	PubMed=23851445

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

10,12

D13S317

10,12

D16S539

11,13

D18S51

15,19

D19S433

13,14

D21S11

D2S1338

18,24

D3S1358

14,15

D5S818

11,12

D7S820

10,12

D8S1179

10,13

FGA

19,21

Penta D

Penta E

5,14

TH01

6,9

TPOX

8,11

vWA

15,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.

Leuk. Lymphoma 57:1015-1020(2016).

DOI PubMed

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

DOI PubMed PMC

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Robetorye R.S., Aguiar R.C.T.

Blood 113:6681-6690(2009).

DOI PubMed PMC

Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.

Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.

Genes Chromosomes Cancer 33:225-234(2002).

DOI PubMed

p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.

Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.

Leuk. Lymphoma 19:165-171(1995).

DOI PubMed

A human lymphoma cell line with multiple immunoglobulin rearrangements.

Minden M.D.

J. Clin. Invest. 89:1014-1020(1992).

DOI PubMed PMC

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

innovationbridge.com